Clinical Trials in Slovakia

• A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended
  2023-507415-35-00 Phase III Psoriatic Arthritis Sun Pharmaceutical Industries Limited
• A Study of Oral Tazemetostat in Subjects With Moderate and Severe Liver Impairment With Advanced solid tumors or hematological malignancies Ended
  2024-517141-13-00 Phase I (Other) Advanced solid tumors, or hematological malignancies and nor… Epizyme Inc.
• An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv… Ended
  2023-507493-41-00 Phase III relapsing multiple sclerosis (RMS) Novartis Pharma AG
• Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended
  2023-504207-89-00 Phase III Retinopathy of prematurity Bayer AG
• Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended
  2022-501018-78-00 Phase III Axial Spondyloarthritis Abbvie Deutschland GmbH & Co. KG
• Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Ended
  2023-508956-20-00 Phase III Hidradenitis suppurativa Novartis Pharma AG
• This trial will evaluate the safety and efficacy of HepaStem compared to placebo in patients with a cirrhotic liver condition called Acute o… Ended
  2022-500252-28-00 Phase II Cirrhotic patients who are hospitalized for Acute on chronic… Cellaïon SA
• A Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the … Ended
  2023-509134-19-00 Phase III Myopia Sydnexis Inc.
• A Multicenter Open-label Extension Study to Evaluate the Long-term Safety of Cenobamate Adjunctive Therapy in Subjects with Primary Generali… Ended
  2023-506688-32-00 Phase III Primary Generalized Tonic-Clonic Seizures Sk Life Science Inc.
• Phase 3b/4 Study in Rheumatoid Arthritis Ended
  2023-508022-10-00 Phase IV Rheumatoid Arthritis Eli Lilly & Co.
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 Phase III Adults at high risk of cardiovascular events without prior M… Amgen Inc.
• A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Su… Ended
  2023-506687-13-00 Phase III Primary Generalized Tonic-Clonic Seizures Sk Life Science Inc.
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II SARL
• Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease Ended
  2023-510426-33-00 Phase III Moderately to Severely Active Crohn's Disease Celgene International II S.a.r.l.
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 Phase III Multiple sclerosis (MS) F. Hoffmann-La Roche AG
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi… Ended
  2024-510727-19-00 Phase II Crohn's Disease (CD) AbbVie Deutschland GmbH & Co. KG
• A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped… Ended
  2023-504711-32-00 Phase III Ulcerative Colitis AbbVie Deutschland GmbH & Co. KG
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 Phase III Reversal of anticoagulation effect in patients on a FXa inhi… Astrazeneca AB
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended
  2022-502233-25-00 Phase III Schizophrenia Neurocrine Biosciences Inc.
• A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors Ended
  2023-503243-34-00 Phase I (Other) Solid tumor Incyte Corp.
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended
  2023-506487-13-00 Phase III Hormone receptor-positive, her2-negative advanced/metastatic… Pfizer Inc.
• A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended
  2023-509206-29-00 Phase III Neovascular age-related macular degeneration (nAMD) Rophibio Inc.

Showing 457–478 of 478 trials